Abstract
1. In nine healthy male subjects the kinetics of nitrendipine were assessed after i.v. administration and its absorption profile was studied when given by a tablet formulation and by an osmotic pumping device (Osmet) with a zero-order in vitro release of 2.62 +/- 0.19 mg h-1 for 13 h. 2. Plasma concentrations of nitrendipine and its pyridine metabolite, heart rate and blood pressure were determined at regular intervals after drug administration. 3. After i.v. nitrendipine, the plasma concentration declined triexponentially with a mean terminal elimination half-life of 11.7 +/- 5.4 h. The mean systemic plasma clearance was 1.47 +/- 0.22 l min-1. 4. Administration of the Osmet resulted in a relatively smooth plasma concentration-time profile in comparison with the tablet. The mean plateau concentration was 2.63 +/- 1.31 ng ml-1 and the duration of this plateau was 10.7 +/- 3.2 h. The intake of food gave rise to a transient increase of the plasma concentration of both nitrendipine and its pyridine metabolite. 5. The mean bioavailability of nitrendipine from the Osmet (8.2 +/- 1.6%) was lower than from the tablet (11.1 +/- 4.5%), which is probably due to release of nitrendipine in lower parts of the G.I. tract where absorption is not or less possible. 6. Intravenous administration caused a transient decrease in DBP of 26 +/- 4%, accompanied by a maximal reflex tachycardia of 46 +/- 17%. No clear haemodynamic effects were observed after oral administration. The Osmet produced less side-effects (headache) than the tablet.
MeSH Terms
Absorption
Administration, Oral
Adult
Biological Availability
Blood Pressure/drug effects
Humans
Infusion Pumps
Infusions, Intravenous
Male
Nitrendipine/administration & dosage,adverse effects,pharmacokinetics,pharmacology
Random Allocation
Tablets
Chemicals
Tablets
Nitrendipine
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Soons P A
Center for Bio-Pharmaceutical Sciences, University of Leiden, The Netherlands.
de Boer A G
van Brummelen P
Breimer D D
References (24)
24 references, click to expand
-
Gas chromatographic analysis of nitrendipine and its pyridine metabolite in human plasma.
J Chromatogr. 1988 Jul 15;428(2):362-8
PMID: 3215939
-
Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration.
Br J Clin Pharmacol. 1987 Nov;24(5):561-9
PMID: 3435690
-
Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations.
Ann Biomed Eng. 1976 Dec;4(4):343-53
PMID: 1020825
-
Mathematical basis of point-area deconvolution method for determining in vivo input functions.
J Pharm Sci. 1978 May;67(5):663-5
PMID: 641805
-
Zero-order rectal delivery of theophylline in man with an osmotic system.
J Pharmacokinet Biopharm. 1982 Oct;10(5):525-37
PMID: 7166736
-
Rectal and intravenous propranolol infusion to steady state: kinetics and beta-receptor blockade.
Clin Pharmacol Ther. 1984 Feb;35(2):148-55
PMID: 6319066
-
Nifedipine: kinetics and dynamics in healthy subjects.
Clin Pharmacol Ther. 1984 Jun;35(6):742-9
PMID: 6734025
-
ELSMOS--an extended least squares modelling system in FORTRAN IV for mini- or micro-computer implementation.
Comput Programs Biomed. 1984 Feb-Apr;18(1-2):43-9
PMID: 6547655
-
Nifedipine kinetics and dynamics during rectal infusion to steady state with an osmotic system.
Clin Pharmacol Ther. 1984 Sep;36(3):396-401
PMID: 6467800
-
Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man.
Biochem Pharmacol. 1984 Nov 15;33(22):3721-4
PMID: 6508829
-
The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy.
J Pharm Pharmacol. 1984 Nov;36(11):740-2
PMID: 6150976
-
Comparison of the acute hemodynamic effects of nifedipine with nitrendipine and a study of the electrophysiological effects of nitrendipine in man.
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1011-5
PMID: 6085358
-
Safety aspects of long-term nitrendipine therapy.
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1063-6
PMID: 6085368
-
Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers.
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S968-73
PMID: 6085386
-
Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects.
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S974-6
PMID: 6085387
-
Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency.
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S977-81
PMID: 6085388
-
Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.
Drugs. 1985 Sep;30(3):182-274
PMID: 2412780
-
Hemodynamic and metabolic effects of the calcium channel blocking agent nitrendipine.
Clin Pharmacol Ther. 1986 Apr;39(4):389-94
PMID: 2937598
-
The application of stable isotopes to studies of drug bioavailability and bioequivalence.
J Clin Pharmacol. 1986 Jul-Aug;26(6):419-24
PMID: 3734130
-
The effects of oral nitrendipine and propranolol, alone and in combination, on hypertensive patients with special reference to AV conduction.
Br J Clin Pharmacol. 1986 Oct;22(4):463-7
PMID: 3533128
-
Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans.
Clin Pharmacol Ther. 1987 Jan;41(1):26-30
PMID: 3802702
-
Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.
Drugs. 1987 Feb;33(2):123-55
PMID: 3552592
-
Pharmacokinetics and pharmacodynamics of nifedipine infusion in normal volunteers.
Br J Clin Pharmacol. 1987 Jun;23(6):693-701
PMID: 3606929
-
Commentary: a physiological approach to hepatic drug clearance.
Clin Pharmacol Ther. 1975 Oct;18(4):377-90
PMID: 1164821